NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 05/02/23

2023-05-02 08:26:46 ET The U.S. Food and Drug Administration (FDA) cleared NeuroBo Pharmaceuticals' ( NASDAQ: NRBO ) investigational new drug (IND) application seeking to start a trial of liver disease drug DA-1241. The company plans to begin a two-part, phase 2a trial of...

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH PR Newswire Initiation of Phase 2a Clinical Trial Expected to Occur in Q3 2023 BOSTON , May 2, 2023 /PRNewswire/ -- NeuroBo Pharmac...

2023-04-17 11:15:14 ET There were a lot of different micro-trends to watch when it came to penny stocks last week. Whether it was stocks with high short interest, a low float, insider trading activity, or unusual activity, take your pick. We noticed an even more active search for penn...

NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH PR Newswire BOSTON , April 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage bio...

2023-03-30 17:20:22 ET NeuroBo Pharmaceuticals press release ( NASDAQ: NRBO ): FY GAAP EPS of -$5.43. Cash and Cash Equivalents were $33.4 million as of December 31, 2022, compared with $16.4 million as of December 31, 2021. Research and Development (R&D) Expenses ...

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results PR Newswire Company Pipeline to Focus on Cardiometabolic Disease Cash and Cash Equivalents to Fund the Company into 2024 BOSTON , March 30, 2023 /PRNewswire/ -- NeuroBo Pharmaceuti...

NeuroBo Pharmaceuticals ( NASDAQ: NRBO ) has appointed Joseph Hooker as Interim Chief Executive Officer and President. Mr. Hooker's appointment follows Gil Price, M.D.'s decision to retire from his position as President and Chief Executive Officer of NeuroBo. The Board plans t...

NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President PR Newswire Experienced Executive Brings Approximately 40 Years of Pharmaceutical, Clinical Development and Operational Experience BOSTON , Jan. 18, 2023 /PRNe...

Saying 2022 was a “wild” year in the stock market is quite an understatement, in my opinion. Not only did we see a crash, but plenty of well-known companies became penny stocks . Yes, that’s correct; by definition, notable names slipped below the $5 threshold. While that ...

3 Tips for Mitigating Risk With Penny Stocks Penny stocks are a popular option for those looking to increase their investment portfolios and potentially create a return on their investments. While penny stocks can be a great way to get into trading, they also come with higher levels of ri...